Financial Performance - The company's revenue for Q1 2024 was ¥482,586,774.29, a decrease of 32.59% compared to ¥715,925,262.60 in the same period last year[5] - Net profit attributable to shareholders was ¥100,017,772.21, down 40.90% from ¥169,225,122.04 year-on-year[5] - Basic and diluted earnings per share were both ¥0.17, a decline of 41.38% compared to ¥0.29 in the same period last year[5] - The company experienced a 40.73% decline in operating profit, which was ¥127,229,268.83 compared to ¥214,661,670.74 in the previous year[8] - The total operating profit for Q1 2024 was CNY 127,229,268.83, down from CNY 214,661,670.74 in Q1 2023, indicating a decrease of about 41%[21] - The company reported a total comprehensive income of CNY 90,746,847.26 for Q1 2024, down from CNY 167,284,723.54 in Q1 2023, reflecting a decline of approximately 46%[22] Cash Flow and Assets - The net cash flow from operating activities decreased by 53.81% to ¥25,053,971.39 from ¥54,238,486.87 in the previous year[5] - Cash and cash equivalents at the end of Q1 2024 were ¥932,852,847.46, down 12.0% from ¥1,058,103,450.21 at the beginning of the period[17] - Cash received from investment recoveries increased by 577.47% to CNY 98,233,132, attributed to the redemption of financial products[9] - The net cash flow from investing activities was negative at CNY -116,407,282.55, compared to CNY -68,739,822.89 in the previous year, indicating a worsening of cash outflow[23] Expenses and Liabilities - Total operating costs for Q1 2024 were ¥354,632,534.26, down 29.1% from ¥500,559,789.53 in Q1 2023[19] - Income tax expenses fell by 40.36% to CNY 27,176,510, reflecting a year-on-year decline in revenue and profit[9] - The company's operating expenses decreased by 35.41% to CNY 74,949,690 compared to the previous period, mainly due to higher donation expenses last year[9] - Total liabilities decreased to ¥898,601,729.13, down 19.7% from ¥1,119,082,599.87 at the beginning of the year[18] Accounts Receivable and Impairment - Accounts receivable increased by 163.91% to ¥208,759,775.18, primarily due to annual credit granted to distributors[8] - The company incurred a credit impairment loss of CNY 13,516,871.34 during the quarter, compared to CNY 7,285,965.25 in the same period last year, reflecting an increase of approximately 85%[21] Shareholder Information and Future Plans - The total number of ordinary shareholders at the end of the reporting period was 20,015, with the largest shareholder holding 62.07%[11] - The company plans to unlock 6,147,976 shares from the first employee stock ownership plan, representing 1.05% of the total share capital[13] - The actual controller and chairman, Zou Xun, announced a plan to increase his shareholding by at least CNY 5 million within six months, reflecting confidence in the company's future[14] - The company plans to focus on market expansion and new product development in the upcoming quarters[19] Research and Development - Research and development expenses decreased by 54.78% to ¥33,086,145.88 from ¥73,161,443.46 in the previous year[8] - Research and development expenses decreased to ¥33,086,145.88, a reduction of 54.8% from ¥73,161,443.46 in the previous year[19] Other Financial Metrics - The weighted average return on equity was 3.44%, down from 5.84% in the same period last year[5] - The company reported a significant increase in asset disposal gains, amounting to ¥4,553,284.87, compared to a loss of ¥1,490,061.62 in the previous year[8] - The company reported a foreign exchange gain of CNY 98,307.26, compared to a loss of CNY -1,940,398.50 in the previous year, showing a significant improvement[23] - The company reported a significant increase in accounts receivable, which rose to ¥208,759,775.18 from ¥79,102,613.44, indicating a potential increase in sales or credit terms[17]

Revenue and Profit Performance - Revenue for the first quarter of 2024 was RMB 482.59 million, a decrease of 32.59% compared to the same period last year[6] - Net profit attributable to shareholders of the listed company was RMB 100.02 million, down 40.90% year-on-year[6] - Total operating income for the first quarter of 2024 was RMB 482.59 million, a decrease from RMB 715.93 million in the same period last year[37] - Net profit decreased to 100,017,772.21 from 169,225,122.04, a 40.9% drop[50] - Comprehensive income attributable to parent company owners was RMB 90,746,847.26, compared to RMB 167,284,723.54 in the previous period[51] - Basic and diluted earnings per share were both RMB 0.17, down from RMB 0.29 in the previous period[51] Cash Flow and Financial Activities - Net cash flow from operating activities was RMB 25.05 million, a decrease of 53.81% compared to the same period last year[6] - Cash paid for goods and services increased by 187.23% to 253,209,242.38, primarily due to higher payments for raw materials[10] - Cash received from investment returns decreased by 93.13% to 1,501,852.82, mainly because investment income from financial products was not received in this period[10] - Cash received from other investment activities increased by 762,905.05% to 171,737,403.51, mainly due to the maturity of equity instruments and fixed deposits[10] - Cash paid for investments increased by 661.64% to 141,357,716.09, primarily due to the renewal of matured financial products[10] - Cash received from borrowing decreased by 60.25% to 57,200,000.00, mainly because loans were not fully renewed upon maturity[10] - Cash paid for debt repayment increased by 422.43% to 142,824,401.28, mainly due to a higher number of loans maturing[10] - Cash received from sales of goods and services was RMB 505,614,745.70, a decrease from RMB 570,932,590.75 in the previous period[51] - Net cash flow from operating activities was RMB 25,053,971.39, compared to RMB 54,238,486.87 in the previous period[51] - Net cash flow from investing activities was negative RMB 116,407,282.55, compared to negative RMB 68,739,822.89 in the previous period[52] - Net cash flow from financing activities was negative RMB 101,543,337.74, compared to positive RMB 115,975,857.88 in the previous period[52] - The net increase in cash and cash equivalents was negative RMB 192,798,341.64, compared to positive RMB 99,534,123.36 in the previous period[52] - The ending balance of cash and cash equivalents was RMB 657,486,886.22, down from RMB 871,787,078.06 in the previous period[52] Assets and Liabilities - Total assets at the end of the reporting period were RMB 3.81 billion, a decrease of 3.29% compared to the end of the previous year[6] - Accounts receivable increased by 163.91% to RMB 208.76 million, mainly due to annual credit granted to distributors[9] - Short-term borrowings decreased by 40.30% to RMB 163.70 million, as some loans were not renewed upon maturity[9] - Long-term borrowings increased by 33.42% to RMB 98.63 million, mainly due to the renewal of long-term loans for the Shanghai subsidiary[9] - Total current assets decreased to 2,113,520,329.69 from 2,196,046,491.93, with a notable decrease in monetary funds to 932,852,847.46[17] - Total owner's equity increased to 2,907,757,658.99 from 2,816,961,724.60, with undistributed profits rising to 1,357,439,151.55[19] - Fixed assets increased to 1,046,123,748.81 from 1,062,985,929.61, showing a slight decrease[47] - Construction in progress rose to 27,654,865.48 from 21,238,492.38, indicating a 30.2% increase[47] - Intangible assets decreased to 147,105,049.71 from 153,556,485.57, a 4.2% drop[47] - Total non-current assets increased to 1,692,839,058.43 from 1,739,997,832.54, a 2.7% increase[47] - Total assets grew to 3,806,359,388.12 from 3,936,044,324.47, a 3.3% increase[47] - Short-term borrowings decreased to 163,700,332.36 from 274,200,540.00, a 40.3% drop[47] - Accounts payable increased to 102,445,016.15 from 200,190,074.02, a 48.8% increase[47] - Contract liabilities rose to 14,702,491.78 from 75,990,998.94, a 80.7% increase[47] Expenses and Costs - R&D expenses decreased by 54.78% to RMB 33.09 million, primarily due to reduced research collaboration and testing fees for Shanghai Baochuan projects[9] - Operating expenses decreased by 35.41% to 74,949.69, mainly due to higher donation expenses in the previous period[10] - Income tax expenses decreased by 40.36% to 27,176,509.91, in line with the decline in revenue and profit[10] - Operating costs for the first quarter of 2024 were RMB 354.63 million, down from RMB 500.56 million in the previous year[37] - Sales expenses for the first quarter of 2024 were RMB 155.07 million, compared to RMB 181.90 million in the same period last year[37] - R&D expenses for the first quarter of 2024 were RMB 33.09 million, a significant decrease from RMB 73.16 million in the previous year[37] - The company's financial expenses for the first quarter of 2024 were negative RMB 1.50 million, compared to RMB 5.24 million in the same period last year[37] Shareholder and Ownership Information - The company's largest shareholder, Guilin Sanjin Group, holds 62.07% of the shares, totaling 364,679,300 shares[29] - Weng Yuling, a domestic natural person, holds 4.99% of the shares, totaling 29,300,061 shares[29] - Zou Zhun, a domestic natural person, holds 3.87% of the shares, totaling 22,764,878 shares[29] - The company's first employee stock ownership plan unlocked 6,147,976 shares, representing 1.05% of the total shares[32] - Zou Xun, the company's actual controller, chairman, and president, plans to increase his shareholding by at least RMB 5 million within six months starting from March 2, 2024[33] Other Financial Metrics - Financial expenses turned negative to RMB -1.50 million, a decrease of 128.52%, mainly due to reduced loan interest[9] - Other comprehensive income decreased by 40.81% to RMB -31.99 million, primarily due to foreign currency investment losses[9] - Other comprehensive income decreased to -9,270,924.95 from -1,940,398.50, a 377.8% drop[50] - The company's first quarter report was unaudited[52]

证券代码：002275 证券简称：桂林三金 公告编号：2024-013 桂林三金药业股份有限公司 关于召开2023年度股东大会的通知 6．会议的股权登记日：2024年5月9日（星期四） 3．会议召开的合法、合规性：本次股东大会的召开符合有关法律法规、深圳 证券交易所业务规则和公司章程等的规定。 4．会议召开的日期、时间： 现场会议的召开时间：2024年5月16日（星期四）下午14:30； 网络投票时间：2024年5月16日。其中：通过深圳证券交易所交易系统投票的 时间为2024年5月16日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证券 交易所互联网投票系统（http://wltp.cninfo.com.cn）投票时间为2024年5月16 日9:15-15:00期间的任意时间。 5．会议的召开方式：本次年度股东大会采取现场表决与网络投票相结合的方 式，公司将通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网络 形式的投票平台，公司股东可以在网络投票时间内通过上述系统行使表决权。公 司股东只能选择现场投票、网络投票表决方式中的一种方式。同一表决权出现重 复表决的，以第一次 ...

| | | | 一、审计报告……………………………………………………… | 第 | 1—5 | | 页 | | --- | --- | --- | --- | --- | | 二、财务报表……………………………………………………… 第 6—13 | | | | 页 | | （一）合并资产负债表…………………………………………… 第 | | | 6 | 页 | | （二）母公司资产负债表………………………………………… 第 | | | 7 | 页 | | （三）合并利润表………………………………………………… 第 | | | 8 | 页 | | （四）母公司利润表……………………………………………… 第 | | | 9 | 页 | | （五）合并现金流量表……………………………………………第 | | 10 | | 页 | | （六）母公司现金流量表…………………………………………第 | | 11 | | 页 | | （七）合并所有者权益变动表……………………………………第 | | 12 | | 页 | | （八）母公司所有者权益变动表…………………………………第 | | 13 | | 页 | 三、财务报表附注… ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002275 证券简称：桂林三金 公告编号：2024-011 桂林三金药业股份有限公司 关于调整第八届董事会审计委员会委员的公告 桂林三金药业股份有限公司（以下简称"公司"）于2024年4月24日召开第 八届董事会第九次会议，审议通过了公司《关于调整第八届董事会审计委员会委 员的议案》。 根据中国证券监督委员会颁布的《上市公司独立董事管理办法》的最新规定， 审计委员会成员应当为不在上市公司担任高级管理人员的董事。公司董事会同意 对第八届董事会审计委员会委员进行相应调整，公司董事、副总裁、财务负责人 谢元钢先生不再担任公司第八届董事会审计委员会委员职务。 为保障公司第八届董事会审计委员会的正常运行，公司董事会同意选举董事 徐劲前先生担任第八届董事会审计委员会委员，任期自本次董事会审议通过之日 起至本届董事会任期届满之日止。除上述委员调整外，董事会审计委员会其余成 员保持不变，调整后公司第八届董事会审计委员会委员为刘焕峰先生、莫凌侠女 士及徐劲前先生，其中刘焕峰先生为审计委员会召集人。 本次调整事项在公司董 ...

桂林三金药业股份有限公司董事会审计委员会 对2023年度会计师事务所履行监督职责情况报告 根据《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第1号——主板上市公司规范运作》《桂林三金药业股份有限 公司董事会审计委员会议事规则》等规定和要求，桂林三金药业股份有限公司 （以下简称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽职守，认 真履职。现将审计委员会对公司年审会计师事务所2023年度履行监督职责的情 况报告如下： 一、2023年年审会计师事务所的基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | --- | --- | --- | --- | | 成立日期 | 2011年7月18日 | 组织形式 特殊普通合伙 | | | 注册地址 | | 浙江省杭州市西湖区灵隐街道西溪路128号 | | | 首席合伙人 | 王国海 | 上年末合伙人数量 238人 | | | 上年末执业人 | 注册会计师 | 2,272人 | | | 员数量 | | 签署过证券服务业务审计报告的注册会计师 836人 | | | 2022年（经审 计）业务收入 | 业务收入 ...

证券代码：002275 证券简称：桂林三金 公告编号：2024-005 桂林三金药业股份有限公司 关于2023年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称"公司"）于2024年4月24日召开第 八届董事会第九次会议、第八届监事会第六次会议，审议通过了公司《2023年度 利润分配预案》，该议案需提交公司2023年度股东大会审议通过后方可实施。具 体内容如下： 一、2023年度利润分配预案情况 经天健会计师事务所（特殊普通合伙）审计，2023年度公司合并利润表实现 归属于母公司所有者的净利润为421,298,789.06元，截至2023年12月31日，公司 合并资产负债表未分配利润为1,257,372,292.21元，母公司资产负债表未分配利 润为1,894,909,970.54元。 2023年度利润分配预案为：以2023年末公司总股本587,568,600股为基数， 向全体股东每10股派发现金股利3.00元（含税），预计共分配现金股利 176,270,580.00元(含税)；不送红股，不以资本公积转增 ...

股票代码：002275 股票简称：桂林三金 公告编号：2024-007 桂林三金药业股份有限公司 关于使用自有闲置资金进行委托理财的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1．投资种类：桂林三金药业股份有限公司（以下简称"公司"）拟通过商 业银行、证券公司、信托公司等金融机构购买安全性高、流动性好、风险可控、 稳健的短期理财产品，包括银行理财、收益凭证、信托计划、资产管理计划、货 币型基金等以及其他根据公司内部决策程序批准的理财对象及理财方式，不得参 与高风险投资类业务。 2．投资金额：根据公司及控股子公司目前的资金状况，投资金额不超过6 亿元。在上述额度内，资金可以滚动使用。 3．特别风险提示：虽然投资产品属于风险较低的投资品种，但金融市场受 宏观经济影响较大，不排除该项投资受到市场波动的影响，公司将根据经济形势 以及金融市场的变化适时适量的实施，因此投资理财的未来实际收益不可预期。 敬请广大投资者注意投资风险。 一、投资情况概述 1.投资目的：在确保公司日常经营资金需求和资金安全的前提下，最大限度 地提高公司自有资金的使用效率 ...

股票代码：002275 股票简称：桂林三金 公告编号：2024-010 桂林三金药业股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 公司董事会、独立董事、持有 1%以上有 | 股东买入公司有表决权的股份违反《证 | | --- | --- | | 表决权股份的股东等主体可以作为征集人， | 券法》第六十三条第一款、第二款有关规定 | | 自行或者委托证券公司、证券服务机构，公 | 的，该超过规定比例部分的股份在买入后的 | | 开请求公司股东委托其代为出席股东大会， | 三十六个月内不得行使表决权，且不计入出 | | 并代为行使提案权、表决权等股东权利。征 | 席股东大会有表决权的股份总数。 | | 集股东权利的，征集人应当披露征集文件， | | | 公司应当予以配合。禁止以有偿或者变相有 | 公司董事会、独立董事、持有 1%以上有 | | 偿的方式征集股东权利。公开征集股东权利 | 表决权股份的股东或者依照法律、行政法规 | | 违反法律、行政法规或者国务院证券监督管 | 或者中国证监会的规定批准设立的投资者保 ...

桂林三金药业股份有限公司 独立董事工作制度 （2024 年 4 月修订） 第一章 总则 第一条 为进一步完善桂林三金药业股份有限公司（以下简称"本 公司"或"公司"）的治理结构，充分发挥独立董事在公司规范运作中的 作用，强化对内部董事及经理层的约束和监督机制，保护投资者特别是 社会公众股股东的合法利益，促进公司规范运作，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》、《上市 公司独立董事管理办法》、《国务院办公厅关于上市公司独立董事制度改 革的意见》（以下简称"《指导意见》"）、《深圳证券交易所股票上市 规则》等法律、法规、规章及《桂林三金药业股份有限公司章程》（以 下简称"《公司章程》"）的规定，特制定本制度。 第二章 一般规定 第二条 独立董事是指不在公司担任除董事外的任何其他职务，并 与公司及公司主要股东、实际控制人不存在直接或者间接利害关系，或 者其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受上市公司及其主要股东、实际控 制人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按 法律、行政法规、中国证券监督管 ...